LOS ANGELES, CA–(Marketwired – Jan 13, 2014) – SK3 Group, Inc.’s (OTC Pink: SKTO) subsidiary Medical Greens (“the Company”) is pleased to announce that Berkeley Bio-Organic Research Laboratories is seeking participants to test their new proprietary cannabinoid-based skin care products — Dharmanol™ Topikoil™, and T-Hydrocan™ Topikoil™.
Numerous scientific studies, as well as a host of anecdotal evidence, have shown that phyto-cannabinoids, and other elements of cannabis / hemp, are active against various types of skin disease. Research by Manuel Guzman at Complutense University in Madrid, Spain has shown that cannabinoids decreased cancer cell proliferation and spreading, decreased density of blood vessels that provide nutrients to tumors, increased cancer cell death, and inhibited tumor-cell metastatic spreading into nearby organs. Much anecdotal evidence on the internet and elsewhere has shown that cannabis oil, when placed on a wart, mole, discoloration, or other growth, can cause numerous types of skin imperfections to simply disappear in just a few weeks with daily treatment.
Berkeley Bio will be testing two types of its proprietary Topikoil™. T-Hydrocan™ Topikoil™ will be made with a substantial dose of whole-plant cannabis extract containing fully activated (decarboxylated) cannabinoids, as well as a wide array of terpenes, terpenoids, and other steam-soluble elements of cannabis / hemp. Dharmanol™ Topikoil™ contains non-psychoactive CBD (cannabidiol) and a wide array of other non-psychoactive cannabinoids from cannabis / hemp.
While the initial testing and rollout will focus on medical cannabis patients in California, the Company intends to roll out Dharmanol™ Topikoil™ nationwide based on the applicable regulations of each state and the US Government.
Those wishing to participate will be provided with several different topical preparations (lotions / salves) and will be required to live in California and keep accurate records, including taking before and after pictures. The testing will begin in one to two months. To sign up, please email your contact information to firstname.lastname@example.org.
“We are very pleased to be announcing these new products,” said Artemus Mayor, President of the Company. “Research has shown very significant effectiveness of medical cannabis against a wide variety of skin ailments, and the stories on the Internet of people casually treating skin imperfections with cannabis topicals abound. Not only is this product chemically different than other similar products on the market, but our new products will have consistent, measurable medical cannabis content that should lead to more effective and targeted dosing. Adding this new delivery system to our Dharmanol™ line of products will substantially increase our market reach into new areas, directly benefiting our bottom line. In addition, our experience with these new products will assist in our development of an extended release transdermal patch product as well as other products.”
The statements in this document have not been evaluated or approved by the FDA. The products and statements referenced in this document are not intended to diagnose, treat, cure, or prevent any disease.
SK3 is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, SK3 brings standardization and transparency to this rapidly growing segment of the alternative care field.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.